Mark Emberton on Focal therapy for men with intermediate risk prostate cancer and a solitary lesion should be standard of care - STOP 6

Focal therapy for men with intermediate risk prostate cancer and a solitary lesion should be standard of care  (STOP 6)

Biography:
Mark Emberton, MD, FRCS is a Professor of Interventional Oncology at the University College London. He is an Honorary Consultant Urologist at University College Hospitals NHS Foundation Trust and Founding Pioneer of The Charity Prostate Cancer UK. Dr. Emberton was appointed Dean of UCL Faculty of Medical Sciences in 2015. Dr. Emberton’s clinical research is aimed at improving the diagnostic and risk stratification tools and treatment strategies for prostate cancer (PCa); he specializes in the implementation of new imaging techniques, nanotechnologies, bio-engineering materials and non-invasive treatment approaches, such as high intensity focused ultrasound and photo-dynamic therapy.
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe